BeiGene Out-Licenses Rights for PD-1 to Novartis in $2.2 Billion Deal
publication date: Jan 12, 2021
Beijing's BeiGene out-licensed ex-China rights for tislelizumab, its China-approved anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. The blockbuster deal includes a $650 million upfront payment to BeiGene, plus up to $1.3 billion in regulatory milestones and $250 million in sales milestones. Novartis will also make royalty payments. Novartis is developing its own PD-1 candidate, spartalizumab, but will reportedly test it as a companion drug, while BeiGene's tislelizumab will be aimed at indications that don’t compete with Novartis's own candidate. More details....
Stock Symbols: (NSDQ: BGNE; HK: 06160)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.